Skip to main content
. 2023 Mar 13;2023(3):CD010941. doi: 10.1002/14651858.CD010941.pub3

4.23. Analysis.

4.23

Comparison 4: Individual tailored versus continuous tapered dexamethasone regimen, Outcome 23: Abnormal neurodevelopmental outcome in survivors assessed (various definitions)